Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces $525 Million Accretive Core-Area Saskatchewan Asset Acquisition (click to learn more) Safe Supply Streaming Portfolio Company Safety Strips, Provides Corporate Update (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cynata Therapeutics Ord Shs V.CYP


Primary Symbol: CYYNF

Healthcare Biotechnology
Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.


OTCPK:CYYNF - Post by User

Cynata Therapeutics Ord Shs > Financing coming
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(9)
•••
Comment by desertbarnacleon Jan 21, 2021 7:35pm
142 Views
Post# 32355843

RE:RE:RE:RE:RE:Financing coming

RE:RE:RE:RE:RE:Financing comingYak,

Well said, many people are just now looking to invest in the EV space along side GM, T Rowe Price ect ectect. 

Funds are being assembled to help people get exposure to the space and I strongly agree, Cypress has yet to recognized by this new market.  Not that these funds matter, our resource will be part of this worldwide build out only now getting started, a major will take us out sooner or later. 

And the ball is their collective court, they all face the risk of waiting, same as we do risk somewhat hanging around.  But, I have no better idea to see another 3X on capital and while it might pale compared to the rise from 5 cents to where we are in percentage terms, 3X a million is still 3 million. And, it could well be much more than that, time will tell, no one can see all ends.

Bob






<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities